>150 mol/L or the presence of other systemic disease(s). All subjects provided written informed consent to participate in the study.
Inflammatory Markers
The inflammatory markers, including white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), albumin, fibrinogen, HS-CRP, and IL-6 were measured. Serum HS-CRP was measured by using particle-enhanced immunonephelometry (Behring Diagnostics, Inc, Somerville, USA), and the plasma IL-6 level was measured by using an enzyme-linked immunosorbent assay (R & D systems, Minneapolis, USA). For the normotensive HS-CRP or IL-6 distribution (log), outliers of >3 SD were excluded because of the possibility that an active inflammatory disease may be present.
Atherosclerotic Markers
The atherosclerotic markers were evaluated by measuring the lipid profile and the intima-medial thickness (IMT) of the carotid artery by using ultrasonographic scanning. The IMT, which has been used recently as a subclinical index of atherosclerosis, 11 was determined by taking the average of 6 readings from the site 1 cm distal to the bifurcation of the right common carotid artery. The sonographer was unaware of the patient's clinical data throughout the study.
Markers of Cardiovascular Damage
To assess the level of subclinical cardiovascular damage, ECG-LVH was measured by using the Sokolow -Lyon criteria (S V1 + R V5 or V6 >35 mm). 12 Echocardiographically, the left ventricular mass (LVM) was calculated by using the Penn Convention 13 and normalized according to body surface area and is known as the LVM index (LVMI). Systolic (ejection fraction; EF) and diastolic (E/A wave ratio through mitral valve) function was also evaluated.
Prediction of a 10-Year Risk of Cardiovascular Disease
The 10-year absolute risk of developing CHD was derived from following the risk-prediction algorithm of the Framingham model, and by using a point score sheet. 14 The risk prediction for CHD was based on categorical variables, such as sex, age, BP, smoking history, total and high-density lipoprotein (HDL) cholesterol, diabetes history, and left ventricular hypertrophy on ECG.
Statistical Analysis
The statistical analysis was conducted by using a Statistical Package for the Social Sciences (SPSS for Windows, Version 10.0.7; SPSS Inc, Chicago, IL, USA). Results are presented as mean ± standard deviation (SD). The distribution of HS-CRP and IL-6 concentration was skewed, and it was log-transformed for analysis. Comparisons were performed by using a 2-tailed Student's t-test and a 1-way ANOVA. Tukey's correction for multiple comparisons was 
Results
Baseline characteristics of the hypertensive and normotensive groups are shown in Table 1 . There were no statistically significant differences between both groups in terms of demographics, physical and lifestyle characteristics, and chemical profile including lipid levels. The average systolic/diastolic BP was 163±19/102±11 mmHg in the hypertensive group and 118±12/79±8 mmHg in the normotensive group (p<0.01). Hypertensives had higher LVMI and carotid IMT, indicating more target organ damage and atherosclerosis. However, most (approximately 85%) of the hypertensive patients had a carotid IMT <1.3 mm or no evidence of plaques, indicating limited atherosclerotic changes.
By comparing the circulating inflammatory markers, the hypertensive group was found to have higher albumin and HS-CRP levels, and a marginally higher WBC level than the normotensive group, however, the 2 groups had similar levels of fibrinogen, ESR, and IL-6 ( Table 2 ). The mean log HS-CRP level of all subjects was 3.56±0.08 mg/L. Based on the Framingham model, the 10-year risk of CHD was higher in the hypertensive group (9.3±7.3 vs 4.3±4.2%) compared with the normotensive group (p<0.01; Table 1 ).
In a correlational analysis, the inflammatory markers, log transformed HS-CRP, IL-6 and WBC were significantly associated with the 10-year risk of CHD in all subjects and in hypertensive group patients (all p<0.01, however, p<0.05 for WBC in the hypertensive group; Table 3 ). In contrast, the inflammatory markers were not associated with the CHD risk in the normotensive group. Table 4 shows the univariate analysis of various inflammatory markers with other parameters, including traditional cardiovascular risk factors and markers of cardiovascular damage in all subjects. Log-transformed HS-CRP was positively associated with BMI, BP, triglyceride (TG), and LVM, and negatively associated with HDL and the E/A ratio from mitral inflow. Log-transformed IL-6 was positively associated with LVM and negatively associated with HDL. WBC, ESR and albumin levels were all shown to be higher in females. Regarding inflammation and atherosclerosis, each inflammatory marker showed no correlation with the carotid IMT or the presence of plaque. Carotid IMT, however, was associated strongly with BP (all parameters, p<0.05) and the developmental risk of future CHD in all subjects (r=0.4, p<0.001), and also with the patients in the hypertensive group (r=0.3, p<0.01). When divided into quartiles according to the log HS-CRP levels (Table 5) , all subjects with HS-CRP in the highest quartile had significantly higher BMI, BP parameters (all p<0.01 when compared with the first quartile) and TG, and lower HDL (p<0.01 for trend) than subjects in the lowest quartile. In addition, the 10-year CHD risk increased progressively with higher HS-CRP, with considerable CHD risk (12.0±8.8%) noted in the highest HS-CRP group. In a similar analysis of hypertensive subjects (Table 6 ), higher quartiles of HS-CRP levels were associated with a higher BMI, a 10-year risk of CHD (12.8±9.2% in the highest vs 6.6±4.0% in the lowest) and lower HDL levels, while association with BP was not significant. The association of carotid IMT with HS-CRP was not significant in the hypertensive group. In a multivariate linear regression analysis assessing the predictors of HS-CRP level, BMI, systolic BP (SBP), and HDL were found to be independent variables (=0.20, 0.23, and -0.21, respectively) that mediated log HS-CRP levels in all subjects, while HDL and BMI were the independent variables (=-0.24 and 0.22, respectively) in hypertensive patients and BMI and fasting glucose (=0.32 and 0.25, respectively) were the independent variables in normotensive subjects (Table 7) .
In a multivariate analysis assessing the association of HS-CRP with the 10-year risk of CHD in all subjects, HS-CRP was the only inflammatory marker that had prognostic significance in addition to traditional risk factors (Table 8) . In a multivariate linear regression assessing the predictors of HS-CRP levels, BMI, SBP, and HDL levels were found to be independent variables (=0.20, 0.23, and -0.21, respectively) that mediated log HS-CRP levels in all subjects.
Discussion
The primary finding of the present study was that hypertensive subjects, even with limited carotid atherosclerotic changes, had higher levels of circulating inflammatory markers including HS-CRP, albumin and WBC levels than normotensive subjects. Among these markers, a higher HS-CRP level was associated with a higher BP and a higher risk score of coronary heart disease independent of traditional risk factors, suggesting that HS-CRP is a useful marker to predict future cardiovascular diseases in hypertension. No significant correlation, however, was found between inflammatory markers and carotid atherosclerosis. Therefore, our data seems to be challenging, because inflammation appears to increase an individual's susceptibility for coronary artery disease, but not through traditional risk factors including carotid atherosclerosis.
There have been numerous studies on the relationship between CRP and cardiovascular risk, yet there are only a few previous studies that have investigated the relationship between CRP and hypertension. These cross-sectional studies showed that hypertensive patients had higher CRP levels compared with normotensive subjects. 15, 16 Although our study limits our ability to infer a causal relationship between BP and HS-CRP and there may be unrecognized confounding factors that affect our interpretation, the Table 4 .
results are consistent with recent beliefs about the relationship between BP and inflammation. Because the difference of CRP was relatively small and CRP overlapped in a considerable portion between normotensives and hypertensives subjects, it is difficult to explain the effect of the inflammatory changes on the CVD risk in hypertension, especially among individuals. However, the data from the present study shows that inflammation augments future CVD risk in addition to traditional risk factors, even in patients with mostly uncomplicated hypertension. The effect of antihypertensive therapy on the inflammatory markers in hypertensive patients and/or normotensive subjects should be confirmed in prospective studies.
In the present study, the hypertensive group was also shown to have higher LVMI and carotid IMT compared with the normotensive group, and as expected, had a significantly higher 10-year risk of CHD at 9.3% (vs 4.3%). Although the causal relationship between markers of inflammation and cardio-carotid hypertrophy was unclear, these were simultaneously elevated in the hypertensive group. A previous study showed that HS-CRP levels are positively correlated with carotid IMT in young patients and suggested that inflammation may be a risk factor for carotid atherosclerosis. 17 Another study showed that the predictive power of CRP for CVD was strongest for those with underlying subclinical atherosclerosis. 5 In the present study, the patients with HS-CRP levels in the higher quartile group had higher BP but did not show a tendency to have greater carotid IMT. The reason may be the low prevalence of carotid atherosclerosis (15.6% of patients had plaques, defined as maximal IMT >1.3 mm) relative to the data shown in the ELSA study (41%), 18 as well as the relatively young age of the patient group. Another reason for the lack of association of carotid atherosclerosis and BP is that the development or progression of atherosclerosis cannot be explained by the BP level itself. There was also no difference in any of the inflammatory changes between patients with and without plaques in carotid arteries. This result cannot currently be explained, but it suggests that other mechanisms such as neuroendocrine hormones may be involved in the progression of atherosclerosis in the hypertensive group. In the present study, the HS-CRP level was significantly correlated with HDL and TG, but not with total cholesterol. There have been few studies that have evaluated the interaction between CRP and HDL. One study showed that CRP was inversely correlated with HDL, and simultaneously high CRP and low HDL levels had additive effects in predicting cardiovascular events. 19 Another study suggested that inflammation reduces the concentration of HDL and possibly compromises the anti-atherogenic properties of these lipoproteins. 20 Another finding in our study was that HS-CRP was significantly correlated with BMI, which was seen in several other studies. The Monica study showed that obese subjects had CRP concentrations twice as high as those with normal BMI, 3 and other cross-sectional studies showed a strong relationship between CRP level and BMI. [21] [22] [23] One study showed that weight loss in obese women was associated with a reduction of CRP levels. 24 Although the exact mechanism for increased CRP in obese patients is not known, it is recognized that IL-6, which is the main modulator for CRP production, is released by adipose tissue. 25 This correlation between CRP and BMI is consistent with the recent concept that chronic inflammatory state is associated with obesity and may induce insulin resistance and endothelial dysfunction, further leading to cardiovascular disease. 26 A study of apparently healthy Japanese people also showed that higher CRP and WBC were associated with more coronary risk factors and poorer physical fitness. 27 The major limitation of the present study was its crosssectional design in which the 10-year risk of developing CVD was derived from the risk prediction algorithm of the Framingham model instead of through a prospective study. However, multicultural studies have shown that this model is a reasonable tool for predicting either the absolute risk of CVD 28 or the rank ordering [29] [30] [31] of CVD risk in men and women. In addition, although the study was designed with single measurements of inflammatory markers, not taking into account any variations that may occur over time, previous studies have shown that CRP levels are reasonably stable over time. 32 In conclusion, we found that the hypertensive group, compared with the normotensive group, had higher levels of circulating inflammatory markers, particularly HS-CRP. In addition, a higher level of HS-CRP was associated with a higher risk of developing CHD, suggesting that inflammation may predict future CHD in hypertensive patients, even if unrelated to atherosclerotic changes such as carotid atherosclerosis. These findings, which need to be confirmed in larger-scale prospective studies, may potentiate the role of inflammation-targeted measures in conjunction with antihypertensive treatment to further reduce future cardiovascular events in hypertensive patients.
